Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission

Pierre Quartier, Ekaterina Alexeeva, Carine Wouters, Inmaculada Calvo, Tilmann Kallinich, Bo Magnusson, Nico Wulffraat, Xiaoling Wei, Alan Slade, Ken Abrams, Alberto Martini

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalArthritis & Rheumatology
Volume70
Publication statusPublished - Sept 2018

Cite this